ATE253934T1 - Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien - Google Patents

Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Info

Publication number
ATE253934T1
ATE253934T1 AT99946776T AT99946776T ATE253934T1 AT E253934 T1 ATE253934 T1 AT E253934T1 AT 99946776 T AT99946776 T AT 99946776T AT 99946776 T AT99946776 T AT 99946776T AT E253934 T1 ATE253934 T1 AT E253934T1
Authority
AT
Austria
Prior art keywords
angiogenic factor
angiopathies
treat microvascular
treat
microvascular angiopathies
Prior art date
Application number
AT99946776T
Other languages
English (en)
Inventor
George F Schreiner
Richard J Johnson
Original Assignee
Scios Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc, Univ Washington filed Critical Scios Inc
Application granted granted Critical
Publication of ATE253934T1 publication Critical patent/ATE253934T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT99946776T 1998-09-09 1999-09-09 Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien ATE253934T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9969498P 1998-09-09 1998-09-09
US12640699P 1999-03-26 1999-03-26
US12661599P 1999-03-27 1999-03-27
PCT/US1999/020480 WO2000013702A2 (en) 1998-09-09 1999-09-09 Use of an angiogenic factor for the treatment of microvascular angiopathies

Publications (1)

Publication Number Publication Date
ATE253934T1 true ATE253934T1 (de) 2003-11-15

Family

ID=27378887

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99968631T ATE260675T1 (de) 1998-09-09 1999-09-09 Methoden zur behandlung der salzabhängigen hypertonie
AT99946776T ATE253934T1 (de) 1998-09-09 1999-09-09 Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99968631T ATE260675T1 (de) 1998-09-09 1999-09-09 Methoden zur behandlung der salzabhängigen hypertonie

Country Status (13)

Country Link
US (3) US6352975B1 (de)
EP (2) EP1112083B1 (de)
JP (2) JP2002532382A (de)
AT (2) ATE260675T1 (de)
AU (2) AU5910599A (de)
BR (2) BR9913533A (de)
CA (2) CA2340320C (de)
DE (2) DE69912815T2 (de)
DK (2) DK1109571T3 (de)
ES (2) ES2216630T3 (de)
IL (2) IL141686A0 (de)
PT (2) PT1109571E (de)
WO (2) WO2000013702A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.
US6783954B2 (en) * 1999-03-05 2004-08-31 Compugen Ltd. VEGF nucleic acid and amino acid sequences
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
IL148674A0 (en) * 1999-11-02 2002-09-12 Genentech Inc Modulation of enos activity and therapeutic uses thereof
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7820178B2 (en) 2001-08-01 2010-10-26 University of Brisol VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
WO2003015605A2 (en) * 2001-08-20 2003-02-27 University Of Virginia Patent Foundation Use of s-nitrosothiol signaling to treat disordered control of breathing
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
US7795213B2 (en) 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
US7335362B2 (en) 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
JP2006068401A (ja) * 2004-09-03 2006-03-16 Kyushu Institute Of Technology 人工血管
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
JP2008537752A (ja) * 2005-04-12 2008-09-25 イントラディグム コーポレイション がんおよび他の新血管形成疾患を処置するためのＲＮＡｉ治療用の組成物および方法
EP1964568B1 (de) * 2005-08-31 2014-03-26 National University Corporation Kagawa University Verwertung der hypertonie/hyperkardie-verhindernden wirkung von d-allose
ES2600781T3 (es) 2008-12-04 2017-02-10 Curna, Inc. Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
GB0921525D0 (en) * 2009-12-08 2010-01-27 Isis Innovation Product and method
AU2018244776B2 (en) 2017-03-30 2023-12-14 Wake Forest University Health Sciences Methods of treatment for kidney disease
CN113418940B (zh) * 2021-06-24 2023-03-14 电子科技大学 一种基于x射线示踪颗粒的检测方法及检测装置

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456550A (en) 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US5240848A (en) 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
WO1990011084A1 (en) 1989-03-24 1990-10-04 The Regents Of The University Of California Endothelial cell growth factor, isolation and expression
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5219739A (en) 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5240714A (en) * 1989-08-29 1993-08-31 Rof Jose M S Non-digoxin-like Na+, K+ -ATPase inhibitory factor
US5318957A (en) * 1992-09-02 1994-06-07 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating angiogenesis
EP0941116B1 (de) * 1996-11-01 2005-01-19 Ark Therapeutics Limited Verwendung von vegf zur herstellung eines medikaments zur behandlung oder verhinderung der intimalen hyperplasie und verabreichungsgerät
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
ES2216630T3 (es) * 1998-09-09 2004-10-16 Scios Inc Metodos de tratar la hipertension dependiente de la sal.

Also Published As

Publication number Publication date
JP2002524421A (ja) 2002-08-06
WO2000013702A3 (en) 2000-09-08
DE69915310D1 (de) 2004-04-08
ES2216630T3 (es) 2004-10-16
ES2211165T3 (es) 2004-07-01
CA2340320A1 (en) 2000-03-16
EP1112083B1 (de) 2003-11-12
DE69915310T2 (de) 2005-03-10
DK1112083T3 (da) 2004-03-08
IL141686A0 (en) 2002-03-10
AU5910599A (en) 2000-03-27
DK1109571T3 (da) 2004-06-21
WO2000013703A2 (en) 2000-03-16
WO2000013702A9 (en) 2000-10-19
BR9913564A (pt) 2001-05-22
EP1109571A2 (de) 2001-06-27
CA2340728A1 (en) 2000-03-16
US6352975B1 (en) 2002-03-05
IL141687A0 (en) 2002-03-10
ATE260675T1 (de) 2004-03-15
WO2000013703A3 (en) 2000-07-06
EP1112083A2 (de) 2001-07-04
US20040224885A1 (en) 2004-11-11
DE69912815D1 (de) 2003-12-18
WO2000013702A2 (en) 2000-03-16
WO2000013703A9 (en) 2000-06-02
BR9913533A (pt) 2001-06-05
PT1112083E (pt) 2004-03-31
PT1109571E (pt) 2004-05-31
CA2340728C (en) 2007-11-27
EP1109571B1 (de) 2004-03-03
JP2002532382A (ja) 2002-10-02
CA2340320C (en) 2006-11-14
AU6028599A (en) 2000-03-27
US20020193288A1 (en) 2002-12-19
DE69912815T2 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
ATE253934T1 (de) Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
ATE230417T1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
DK0987998T3 (da) Decellulering af væv
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
ATE302599T1 (de) Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
DE69839529D1 (de) Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
CY1108563T1 (el) Μεθοδοι και υλικα για τη θεραπεια της ανεπαρκειας (ελλειψης) τεστοστερονης στους ανδρες
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
TR199901703T2 (xx) Siklooksijenaz-2 inhibit�rlerini anti-anjiyojenik ajanlar olarak kullanma y�ntemi.
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
DE50110552D1 (de) Verfahren zur behandlung von instabiler angina pectoris
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE222501T1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
EP1447089A3 (de) Methoden zur Behandlung von Hypertonie und Zusammensetzungen dafür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1112083

Country of ref document: EP

REN Ceased due to non-payment of the annual fee